ABL Bio Inc. (KOSDAQ:298380)

South Korea · Delayed Price · Currency is KRW

89,100

-4,500 (-4.81%)

Aug 11, 2026, 3:30 PM KST

19.60% (1Y)

Market Cap	5.24T +28.9%
Revenue (ttm)	90.32B +226.9%
Net Income	-24.14B
EPS	-452.97
Shares Out	55.99M
PE Ratio	n/a
Forward PE	20,961.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	455,880
Open	93,600
Previous Close	93,600
Day's Range	87,200 - 95,200
52-Week Range	59,800 - 257,500
Beta	0.27
Analysts	Buy
Price Target	257,500.00 (+189.0%)
Earnings Date	Aug 11, 2026

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson’s disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatm... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2016

Employees 102

Stock Exchange KOSDAQ

Ticker Symbol 298380

Full Company Profile

Financial Performance

In 2025, ABL Bio's revenue was 79.35 billion, an increase of 137.55% compared to the previous year's 33.40 billion. Losses were -37.81 billion, -31.92% less than in 2024.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for 298380 stock is "Buy." The 12-month stock price target is ₩257,500, which is an increase of 189.00% from the latest price.

Price Target

₩257,500

(189.00% upside)

Analyst Consensus: Buy

Stock Forecasts